OGT, a Sysmex Group Company, has launched the SureSeq Myeloid Plus panel to detect aberrations in genes implicated in a variety of myeloid disorders. The panel is able to detect a comprehensive range of aberrations including SNVs, indels, ITDs and PTDs within 49 genes. These genes cover those associated with myeloid disorders, including acute myeloid leukaemia, myeloproliferative neoplasms and myelodysplastic syndrome, among others.
Due to OGT’s expertise in bait design, the panel delivers high-coverage uniformity for low-frequency variants, even in difficult-to-sequence AT/GC rich regions and challenging regions covering ITDs and PTDs, which are common somatic variants in acute myeloid leukaemia (AML) often associated with poor prognosis and an aggressive form of the disease. The company says the power of the panel stands testament to the benefits of hybridisation capture over PCR enrichment for high levels of sensitivity and uniformity of coverage.
Phone: 02 9016 3040
Alithea Genomics MERCURIUS Total DRUG-seq transcriptome profiling library preparation kit
The extraction-free, full-length transcriptome profiling library preparation kit is designed to...
Alithea Genomics MERCURIUS FLASH-seq single-cell RNA sequencing kit
The plate-based kit (available in 96- and 384-well formats) features a novel, non-toxic...
WMFTS WMArchitect Interchangeable Parts service for single-use assemblies
Watson-Marlow Fluid Technology Solutions (WMFTS) has introduced WMArchitect Interchangeable Parts...
